New hope for liver cancer patients when first treatment fails
NCT ID NCT07151326
Summary
This study is testing the drug cabozantinib for people with advanced liver cancer (hepatocellular carcinoma) whose disease has gotten worse after standard first-line immunotherapy combinations. The main goals are to see if the drug can control the cancer for at least 6 months and to understand its safety. Researchers will also look for clues in blood and tissue samples to predict who might benefit most from this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Chang Gung Memorial Hospital (Lin-Kou),
Taoyuan District, Taiwan
Contact
Contact
-
Chang-Gung Memorial Hospital, Kaohsiung
Kaohsiung City, Taiwan
Contact
Contact
-
China Medical University Hospital
Taichung, Taiwan
-
Mackay Memorial Hospital
Taipei, 104, Taiwan
Contact
Contact
-
National Cheng-Kung University Hospital
Tainan, Taiwan
Contact
Contact
-
National Taiwan University Hospital
Taipei, 100, Taiwan
Contact
Contact
-
Taichung Veterans General Hospital
Taichung, 407, Taiwan
Contact
Contact
-
Taipei Veterans General Hospital
Taipei, Taiwan
Contact
Contact
-
Tri-Service General Hospital
Taipei, Taiwan
Contact
Contact
Conditions
Explore the condition pages connected to this study.